Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Intellia Therapeutics, Inc. NTLA

Set alert

Price alert · NTLA

All alert types
11.66 USD -0.81 -6.50%

At close

11.63 -0.03 -0.26%

Pre-market · Nov 3, 7:23 AM ET

Bid
11.65 × 2
Ask
11.66 × 2
11.59 Day range 12.61
7.95 52-week range 18.48
YTD
+29.70%
1 year
-10.79%
Open
12.60
Prev close
12.47
Mkt cap
1.63B
Vol
3.88M
Avg vol
4.39M
EPS
-3.35
P/E
0.00
Div yield
0.00%
More statistics
Low
11.59
High
12.61
Forward P/E
-4.55
Beta
1.82
Short ratio
7.63
Inst. own
100.56%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
12.23
200-d avg
13.08
1y target
23.11

5D chart

Chart tools
Interval
1m5m15m30m

Signals (109)
NameTimeAgo
MACD: Sell SignalNov 2, 1:40 PM17 hours ago
RSI: OversoldNov 2, 1:40 PM17 hours ago
RSI: OversoldNov 2, 1:30 PM17 hours ago
MACD: Buy SignalNov 2, 1:05 PM18 hours ago
RSI: OversoldNov 2, 12:40 PM18 hours ago
MACD: Sell SignalNov 2, 12:20 PM19 hours ago
SMA: BearishNov 2, 12:05 PM19 hours ago
MACD: Buy SignalNov 2, 11:40 AM19 hours ago
SMA: BullishNov 2, 11:30 AM19 hours ago
RSI: OversoldNov 2, 10:55 AM20 hours ago
SMA: BearishNov 2, 10:30 AM20 hours ago
MACD: Sell SignalNov 2, 10:05 AM21 hours ago
SMA: BearishNov 2, 10:00 AM21 hours ago
SMA: BullishNov 2, 9:55 AM21 hours ago
SMA: BearishNov 2, 9:40 AM21 hours ago
RSI: OverboughtOct 30, 3:55 PM3 days ago
SMA: BullishOct 30, 3:10 PM3 days ago
MACD: Buy SignalOct 30, 3:05 PM3 days ago
MACD: Sell SignalOct 30, 2:55 PM3 days ago
SMA: BullishOct 30, 1:50 PM3 days ago

Newest 20 of 109.

Analyst view

Consensus: none

Price target (mean) 23.11 +98.2% upside
Target (low)
8.00
Target (mean)
23.11
Target (high)
61.00
Ratings (0m) 20 10 buy · 6 hold · 4 sell
  • Strong buy1
  • Buy9
  • Hold6
  • Sell2
  • Strong sell2

Recommendation trend

  • This month 20
  • 1 month ago 19
  • 2 months ago 19

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

NTLA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.78559-0.89 – -0.71-0.92+14.6%9.77M-29.1%16
Next quarter-0.75096-0.91 – -0.41-0.83+9.5%17.09M-25.8%16
Current year-3.14-3.41 – -2.83-3.81+17.5%51.88M-23.3%17
Next year-2.56-3.62 – 0.97-3.14+18.4%126.26M+143.4%17

Upgrades and downgrades

The latest rating changes

NTLA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 6, 2026BarclaysInitiated—Underweight
Sep 9, 2026CitizensReiteratedMarket OutperformMarket Outperform
Sep 9, 2026WedbushMaintainedNeutralNeutral
Sep 9, 2026HC Wainwright & Co.ReiteratedBuyBuy
Aug 25, 2026CitizensReiteratedMarket OutperformMarket Outperform
Aug 7, 2026Evercore ISI GroupUpgradeIn-LineOutperform
Jul 16, 2026Wolfe ResearchDowngradePeer PerformUnderperform
Jul 10, 2026WedbushMaintainedNeutralNeutral
Jun 16, 2026Canaccord GenuityMaintainedBuyBuy
Jun 15, 2026CitizensReiteratedMarket OutperformMarket Outperform
Jun 15, 2026WedbushReiteratedNeutralNeutral
Jun 15, 2026HC Wainwright & Co.ReiteratedBuyBuy
May 13, 2026BernsteinMaintainedMarket PerformMarket Perform
May 13, 2026HC Wainwright & Co.MaintainedBuyBuy
May 12, 2026Canaccord GenuityMaintainedBuyBuy
May 12, 2026WedbushReiteratedNeutralNeutral
Apr 28, 2026Canaccord GenuityMaintainedBuyBuy
Apr 28, 2026Goldman SachsMaintainedSellSell
Apr 28, 2026Morgan StanleyMaintainedEqual-WeightEqual-Weight
Apr 28, 2026CitizensMaintainedMarket OutperformMarket Outperform
Apr 27, 2026Chardan CapitalMaintainedBuyBuy
Apr 27, 2026BairdMaintainedNeutralNeutral
Mar 4, 2026Jones TradingUpgradeHoldBuy
Mar 3, 2026Canaccord GenuityMaintainedBuyBuy
Mar 3, 2026Leerink PartnersMaintainedOutperformOutperform
Mar 3, 2026RBC CapitalMaintainedSector PerformSector Perform
Mar 3, 2026Wells FargoMaintainedEqual-WeightEqual-Weight
Mar 3, 2026CitizensMaintainedMarket OutperformMarket Outperform
Mar 3, 2026HC Wainwright & Co.MaintainedBuyBuy
Mar 2, 2026Chardan CapitalMaintainedBuyBuy